Cannabidiol (CBD) delivered through specially designed nanoparticles significantly inhibited liver tumor growth in mice, performing comparably to a commonly used chemotherapy drug, according to a study published in the Journal of Drug Delivery Science and Technology. Researchers developed microscopic drug carriers designed to overcome one of the primary obstacles to using CBD therapeutically: its extremely poor solubility in water. They encapsulated approximately 86% of the CBD used and released 70.2% of the compound under conditions designed to simulate the environment inside a tumor. In mice implanted with H22 liver tumors, treatment with the nanomicelles produced “potent tumor growth inhibition” comparable to cyclophosphamide, a chemotherapy and immune-suppressing medication. The findings are preclinical and do not establish that CBD can treat liver cancer in humans.